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Abstract 
 
Purpose: To determine if the supportive care needs of people with pancreatic cancer change 
over time and identify factors associated with current and future unmet needs. 
 
Methods: Australian pancreatic cancer patients completed a self-administered survey 0–6 
months post-diagnosis (n=116) then follow-up surveys 2 (n=82) and 4 months (n=50) later. 
The validated survey measured 34 needs across five domains. Weighted generalised 
estimating equations were used to identify factors associated with having ≥1 current or future 
moderate-to-high unmet need. 
 
Results: The overall proportion of patients reporting ≥1 moderate-or-high-level need did not 
significantly change over time (baseline=70% to 4 months=75%), although there was a non-
significant reduction in needs for patients who had a complete resection (71% to 63%) and an 
increase in patients with locally advanced (73% to 85%) or metastatic (66% to 88%) disease. 
Higher levels of pain (OR 6.1, CI 2.4-15.3), anxiety (OR 3.3, CI 1.5-7.3) and depression (OR 
3.2, CI 1.7-6.0) were significantly associated with current needs. People with pain (OR 4.9, 
CI 1.5-15.4), metastatic disease (OR 2.7, CI 0.7-10.0) or anxiety (OR 2.5, CI 0.7-8.6) had 
substantially higher odds of reporting needs at their next survey. The prevalence of needs was 
highest in the physical/daily living and psychological domains (both 53% at baseline). Pain 
and anxiety had respectively the strongest associations with these domains. 
 
Conclusions: Careful and continued attention to pain control and psychological morbidity is 
paramount in addressing significant unmet needs, particularly for people with metastatic 
disease. Research on how best to coordinate this is crucial.  
 
Key words: Pancreatic cancer, unmet supportive care needs, risk factors, longitudinal study, 
pain, anxiety, depression 
  
3 
 
Introduction 
 
Pancreatic cancer is the fifth most common cause of cancer death in more developed regions 
of the world [1]. There is no screening test for this disease and patients are generally 
identified when already symptomatic, often presenting with unexplained weight loss, back or 
abdominal pain, or obstructive jaundice [2]. Surgical resection of the tumour is the only 
curative therapy, but only 15-20% of patients have tumours that are resectable [3], with most 
patients presenting with advanced disease or comorbidities that preclude resection. 
 
People with pancreatic cancer have the worst survival prognosis of any cancer. Only 20% of 
patients survive the first year and five-year all-stage survival is 6% [4]. Even in those patients 
who undergo curative surgical resection, the five-year survival is only 10-25% [5]. 
Chemotherapy and chemo-radiation options are available for use in neo-adjuvant, adjuvant or 
palliative settings, but for most patients the survival benefit is minimal [2]. Thus, effective 
palliation of symptoms and improvements in quality of life are critically important for the 
majority of patients with pancreatic cancer [6].  
 
Quality of life endpoints have become standard in the evaluation of cancer therapies in 
clinical trials [7] and these are of particular importance in cancers with poor prognosis and 
short median survival. Many studies of pancreatic cancer have compared patient outcomes 
following different treatments and palliative procedures at different stages, but few have 
specifically considered patients’ supportive care needs. 
 
Needs assessment in the context of cancer assesses the person’s desire for action, information 
or support [8]. Quality of life can be improved through meeting people’s supportive care 
needs [9]. However, to facilitate change in patient-reported outcomes, screening must be 
followed with timely provision of interventions that are based on evidence [10, 11]. 
Unfortunately, some patients will decline interventions offered by their health care team 
because they feel they are receiving informal help elsewhere or prefer to manage on their 
own [12]. Thus needs assessment is a sensible approach, asking patients formally if they have 
a desire for further assistance with unresolved concerns. The few longitudinal studies that 
have assessed needs have shown that unmet supportive care needs decrease over time during 
treatment in women with breast cancer [13, 14], following treatment in women with ovarian 
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cancer [15] and in groups of people with a mix of cancer types [16, 17] including those with 
advanced disease [17].  
 
Our previous cross-sectional analysis found that people with newly diagnosed pancreatic 
cancer had very high levels of unmet supportive care needs, particularly with respect to 
alleviating fatigue, pain or psychological distress [18]. However, no population-based studies 
have considered how needs of pancreatic cancer patients may change over time and which 
factors are associated with having unmet needs. Thus, this work used a population-based 
sample to determine the changes in supportive care needs and factors associated with current 
and future unmet needs in people with pancreatic cancer. 
 
Methods 
 
Participants and procedures 
Patients 18 years and over in Queensland, Australia with a suspected or confirmed diagnosis 
of pancreatic cancer between January 2007 and June 2011 were recruited for the Queensland 
Pancreatic Cancer Study (QPCS). This was a Queensland-wide, population-based case-
control study with the aim to examine environmental and genetic risk factors for pancreatic 
cancer. [19]. The study used a rapid ascertainment approach, recruiting patients as early as 
possible through a state-wide network of clinicians in hospitals and private practices, often 
while diagnostic investigations were ongoing. Controls were randomly selected from the 
Australian Electoral Roll (enrolling to vote is compulsory for Australian Citizens aged 18 
years or more). Participants completed a face-to-face or telephone interview during which we 
asked about socio-demographic and lifestyle factors, medical and occupational history and 
family history of cancer. Participants were also asked to donate a blood sample and to give 
consent for us to review their medical records. Trained research nurses subsequently 
reviewed the medical records of all potential cases recruited and 704 (84%) had a confirmed 
diagnosis of pancreatic cancer.  
 
From July 2009 newly recruited QPCS participants with confirmed pancreatic cancer were 
also invited to participate in this longitudinal cohort sub-study of patient-reported outcomes. 
This sub-study involved completing a self-administered mail questionnaire at recruitment and 
follow-up questionnaires 2-monthly until the participant was lost to follow-up or 8 months 
after diagnosis (due to an expected >30% attrition rate at this time). Patients were excluded if 
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they were more than 8 months after diagnosis or if they were physically or mentally unable to 
complete a written questionnaire. Patients were given the information sheet, consent form, 
baseline questionnaire and reply-paid envelope at the end of their QPCS interview where 
possible or by mail soon after and all follow-up questionnaires were administered by mail.  
 
Figure 1 outlines the flow of participant recruitment. Of the 351 eligible QPCS participants 
recruited after July 2009, 97 were excluded and not approached, 57 declined, 23 died shortly 
after receiving the questionnaire and 38 others did not return the questionnaire. The 
remaining 136 QPCS participants completed the baseline patient-reported outcome 
questionnaire (54% of those approached). A further 20 had unusable data for this analysis, 
leaving 116 participants contributing data.  
 
The QPCS and patient-reported outcome sub-study were both approved by the Human 
Research Ethics Committees of the QIMR Berghofer Medical Research Institute and 
participating hospitals.  
 
Measures 
Outcome measure 
The Supportive Care Needs Survey-Short Form (SCNS-SF34) was used to assess needs 
across five domains: psychological (10 items); physical/daily living (5 items); health 
system/information (11 items); patient care/support (5 items); and sexuality (3 items) [20]. 
This tool asks participants to rate their need for help with each item over the past month on a 
5-point scale where 1 = not applicable (no need), 2 = satisfied (need was met), 3 = low unmet 
need, 4 = moderate unmet need, and 5 = high unmet need. Binary categories for any overall 
and domain-specific needs were classified as: ‘no-to-low needs’ versus ‘at least one 
moderate-to-high need’. Summated standardised  scores (ranging from 0 to 100) for any need 
and domain-specific needs were also derived as per the scoring manual [21]. The SCNS-SF34 
is a validated measure; in a sample of patients with a wide range of cancers its five domains 
collectively accounted for 73% of the variance, with Cronbach’s alpha for domains ranging 
from 0.86 to 0.96 [20].  
 
Potential risk factor variables measured 
A range of measures to evaluate risk factors consistent with a social–ecological model were 
assessed [22]. This model theorises that needs can be influenced by demographic 
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characteristics, clinical conditions, personal symptoms, social support, health care provision 
and community level factors. 
 
Demographic variables: Age, sex, marital status and education level were self-reported at 
recruitment.  
 
Clinical variables: Information was extracted from medical records about disease stage, 
whether the patient had undergone a resection of the primary tumour, comorbidities, 
chemotherapy type, dose and dates. Stage and resection were used to construct a disease 
status variable (completed resection - curative disease, locally advanced disease, metastatic 
disease). Dates for chemotherapy and survey completion were cross-referenced to determine 
if participants were receiving chemotherapy at the time they completed each questionnaire.   
 
Self-reported physical and psychological symptoms/wellbeing: Pain was assessed by a single 
item within the FACT- physical wellbeing subscale [23]. Response options to ‘During the last 
7 days I was bothered by pain’ were not at all, a little bit, somewhat, quite a bit and very 
much. Anxiety and depression were assessed using the Hospital Anxiety and Depression 
Scale (HADS) [24]. The two sub-scales, anxiety and depression, each distinguish between 
‘non-case’ (0–7), ‘sub-clinical case’ (8–10), and ‘clinical case’ (11–21).  
 
Self-reported support: Social support was assessed by the FACT- social/family wellbeing 
subscale [23]. Scores were summed across 7 items and the final scores ranged between 0 and 
28, with higher scores indicating better social support.  
 
Health care variables: Information was extracted from medical records about treatment in the 
public or private health system, whether the patient had a care coordinator or care plan and 
whether the patient had seen a palliative care specialist and, if so, the initial date first seen. 
Dates for palliative care and survey completion were cross-referenced to determine if 
participants had seen a palliative care specialist at the time they completed each 
questionnaire.   
 
Remoteness of community: Postcode was used to classify participants as residing in a major 
city, or an inner regional, outer regional, remote or very remote area using the 
Accessibility/Remoteness Index of Australia [25]. 
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Statistical methods  
Not all participants completed all surveys and attrition does not occur at random, so we used 
a series of complex statistical analyses to account for this and to ensure that we could use all 
available data. 
 
The first survey was completed a variable time after diagnosis due to the challenges of 
identifying patients with pancreatic cancer. Thus, we first considered the length of time after 
diagnosis that should contribute to the baseline measure. We compared data from the first 
questionnaire according to completion within 0-2 months, 3-4 months and 5-6 months after 
diagnosis. The proportions with moderate-to-high unmet needs was not significantly different 
according to the timing of first questionnaire completion, although those who completed their 
first questionnaire later tended to have fewer unmet needs (42/53 (79%), 29/46 (63%), 10/17 
(59%), respectively; p=0.12). Baseline data came from initial questionnaires completed by 
patients within 6 months of diagnosis. 
 
We had intermittent missing data for 30 (26%) participants (17 were missing the 2-month 
follow-up; 13 were missing the 4-month follow-up). Intermittent missing data for the 30 
participants were imputed using the average response of the prior and subsequent data points. 
The dataset thereafter contained monotone missing only. To determine the impact of attrition 
(monotone missing) on representativeness [26] we plotted the proportion of patients with 
moderate-to-high unmet needs by time-point. To determine factors associated with attrition 
[26] we compared the characteristics of those who dropped out versus those who did not.  
 
We conducted bivariable analyses, using Chi-squared tests for categorical variables and two-
sample t-test for continuous variables to examine associations between factors of interest and 
the presence of moderate-to-high unmet needs at baseline. We plotted the unadjusted 
relationship between time and moderate-to-high unmet needs stratified by disease status, 
although the sample size within each disease status subgroup was small and statistical 
significance could not be considered.     
 
Finally we fitted multivariable models to examine factors associated with: (a) any; (b) 
physical; or (c) psychological moderate-to-high unmet needs. We examined those factors that 
were statistically significant (p<0.01) in the bivariable analyses as well as age and severity of 
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disease, which were of clinical interest. Longitudinal logistic regression models using 
weighted generalised estimating equations (GEEs) were used to determine factors associated 
with (a) current and (b) future moderate-to-high unmet needs. GEEs account for intrapersonal 
correlations allowing the outcome and independent variables to change over time. Thus we 
were able to use data from all surveys. We defined current unmet needs as those reported at 
the time of each survey and future unmet needs were those reported in the next survey if it 
was completed. Time-specific weights were calculated for each patient using two separate 
logistic regression models where the response variable was observed during either the 2-
month or the 4-month follow-up. Those with imputed data were defined as observed as they 
were still active in the study. Weighting was included in the GEEs to account for the 
unbalanced number of data points for participants who were lost to follow up. Weights were 
calculated as the inverse of the probability of being observed, as estimated from the logistic 
regressions. The probability of being observed at the first time point was defined to equal 
one. Factors associated with being observed during the 2-month follow-up were age and 
prognosis, whereas those associated with being observed during the 4-month follow-up were 
age and number of months post-diagnosis.  
 
Results 
 
 Participants 
On average, participants were 67 years old at diagnosis (SD=10), 60% were men, most (80%) 
were married or had a partner and 58% had a college education or higher (Table 1). These 
characteristics were proportionally similar to the cases enrolled in the QPCS [19]. 
Participants completed the first questionnaire on average 3 months after diagnosis, many 
(61%) were initially treated in the private setting, 44% had a complete resection, 31% had 
metastatic disease and most (83%) had chemotherapy (Table 1).  
 
Characterizing attrition 
Sixty-eight percent (n=79) of participants remained active in the study at the 2-month follow-
up and 42% (n=49) at the 4-month follow-up. Among those who were lost to follow-up, 40% 
(n=27) did so because they were too sick or had died and 24% (n=16) withdrew or did not 
respond. Participants who were lost to follow-up on average had a lower proportion of unmet 
needs at baseline than those with complete data (Figure 2). Those who were too sick, had 
died or were excluded from follow-up because they were >8 months after diagnosis were 
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significantly older than those who completed the study or withdrew for other reasons (Table 
2). Those who ceased follow-up due to death or being too sick were significantly more likely 
to have non-curative disease and slightly (but not statistically) more likely to have anxiety 
and depression (Table 2).  
 
Prevalence of and change in unmet needs over time 
At baseline, 70% of participants reported having at least one moderate-to-high unmet need 
and more than half reported physical (53%) or psychological (53%) needs at moderate-to-
high levels, whereas health system/information (29%), patient care (17%) and sexuality needs 
(13%) were reported less frequently. Overall there were no significant changes over time in 
the proportions reporting moderate-to-high unmet needs (Figure 3 – unadjusted; 
baseline=70% to 4 months=75%  and Table 3 – adjusted odds ratio 0.9 (95% confidence 
interval 0.3,2.1)). Furthermore, the odds of having needs in the future was not significantly 
different depending on whether patients were at baseline or at the 2 month follow-up (Table 3 
– OR 1.2 (CI 0.5,2.7)), although there was an indication from unadjusted stratified analysis of 
a reduction in needs over time for patients who had a compete resection (71% to 63%) and an 
increase in needs over time in patients with locally advanced (73% to 85%) or metastatic 
disease (66% to 88%) (Figure 3).  
 
Factors associated with having at least one current or future moderate-to-high unmet need 
In bivariable analyses no significant associations were found between reporting moderate-to-
high unmet needs and age, sex, marital status, education, place of residence, initial place of 
treatment, having a resection, comorbidities, chemotherapy, social support, having a care 
coordinator or accessing palliative care (Table 1). 
 
Variables retained in the multivariable analyses are presented in Table 3. Higher levels of 
pain, anxiety and depression were significantly associated with current needs. Pain was the 
only factor statistically significantly associated with any future needs, although people with 
metastatic disease and those with anxiety had substantially higher odds of having future 
needs. We considered factors associated with the two most prevalent needs domains and 
found that depression and pain were significantly associated with current physical needs, 
whereas pain and locally advanced disease were the main factors associated with future 
physical needs. Anxiety, depression and pain were associated with current psychological 
needs, and in addition to these factors, those patients with metastatic disease had higher odds 
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of future psychological needs.   
 
Discussion 
This unique study is the first to provide formal population-based longitudinal assessment of 
supportive care needs of patients with pancreatic cancer. The findings provide evidence for 
health professionals and service providers as to which types of unmet needs are prevalent and 
persistent and which risk factors should be considered in assessing the likelihood of ongoing 
needs. We show that unmet needs among pancreatic cancer patients were high at baseline and 
persisted over time. Physical and psychological needs were the most prevalent subcategories, 
with about half the participants reporting these at moderate-to-high levels. While in general, 
patients with non-resectable disease and higher levels of pain, anxiety and depression were at 
higher risk of having unmet supportive care needs, these associations varied across support 
domains and were dependent on whether people were currently experiencing the need or if it 
was a need that they reported during further follow-up. Of note, pain and anxiety had 
respectively the strongest associations with having unmet physical and psychological needs 
both in the present and in the future. The consistency of these two risk factors for unmet 
needs over time may suggest that they are not being adequately addressed or that they are 
associated with rapid disease progression and may be normal with an imminent end of life.  
 
In the last decade, pain and distress have been positioned as the fifth and sixth vital signs in 
cancer care with emphasis placed on the importance of screening [27-29]. Carlson [30] 
concluded that screening for distress and unmet needs facilitates communication around 
emotional complications and, in conjunction with empirical treatment, has the potential to 
significantly improve quality of life. Our findings that pain and distress are extremely 
important in people with pancreatic cancer highlight the need to focus on these issues. People 
with these two risk factors should be closely monitored and receive early referral to palliative 
care.    
 
Our results also indicate those with locally advanced disease are most likely to have current 
and future unmet physical needs. It may be that patients with locally advanced disease are not 
accessing palliative care where their physical needs for things like pain relief would be 
managed. People with metastatic pancreatic cancer were not at immediate elevated risk of 
having unmet psychological needs compared to those with non-metastatic disease but were at 
risk of having these needs in the future. This is most likely linked to their fast disease 
11 
 
progression, development of cancer-related symptoms and increasing fear of death [31]. 
 
In contrast to other longitudinal studied that have assessed unmet needs [13-17] our study 
found that people with pancreatic cancer have persistently high levels of unmet needs and 
that there may be a trend for needs to increase over time in patients who are unable to 
undergo resection of their tumour (i.e. in 80% or more of people with pancreatic cancer [3]). 
Furthermore, our results show that it is the patients with metastatic pancreatic cancer, anxiety 
and pain who are at higher risk of having unmet supportive care needs in the future.  
 
In the setting of advanced cancer, patients and their families require discussions about both 
the goals of their immediate care and planning for their future health care needs [32]. In 
addition to any patients in pain and distress, our data support timely referral of patients with 
non-resectable pancreatic cancer to palliative care where multidisciplinary teams can assess 
and manage the full range of patients’ care needs across physical, psychological, social, 
spiritual, and information domains [33]. We previously reported that fewer than 60% of 
people with non-resectable pancreatic cancer accessed palliative care before our baseline 
survey [18]. This may in part explain the initial high levels of unmet needs. Continuing 
unmet needs most likely reflect worsening quality of life. A longitudinal study of quality of 
life showed that symptom burden significantly increased in the first 3 months post-diagnosis 
with metastatic pancreatic cancer [34]. The majority of advanced pancreatic cancer patients 
have pain at the time of diagnosis, requiring a multidisciplinary approach involving palliative 
care providers as well as medical and radiation oncologists to optimise pain management 
[35].    
 
Our study did not detect differences in the level of unmet needs by remoteness of the 
patients’ residential location, by initial treatment in a public or private hospital or by whether 
a person saw a care coordinator or accessed palliative care. However, this may be due to our 
modest sample size or some reverse causality. For example, people who saw a care 
coordinator or accessed palliative care may have had higher levels of unmet need to start 
with.  
 
This study had several design limitations. The sample size was relatively small, but 
sophisticated statistical analyses used all available cases to identify significant effects which 
were both plausible and of clinical importance. Participants in this sub-study had significantly 
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better prognosis than the larger population of people diagnosed with pancreatic cancer, 
among whom resection is completed for 15% and 58% are diagnosed with metastatic disease 
[36]. We therefore are likely to have underestimated supportive care needs, particular with 
increasing time as our subgroup analysis was indicative of increasing needs over time in 
patients with advanced disease. As participants were required to complete various other study 
components first, the timing of recruitment for this component was some time after diagnosis. 
While we did conduct analyses justifying our pooling of participants who completed their 
first questionnaire 0-6 months after diagnosis, we had not expected recruitment to take so 
long and had set the study protocol to have no further follow-up at 8 months post-diagnosis, 
which resulted in the exclusion of a number of patients. We also had considerable 
intermittent missing data and attrition due to death or incapacity. While we imputed 
intermittent missing data and used weighted GEEs that allowed data to be missing at random, 
it is possible we have further underestimated the level of unmet needs, as those who withdrew 
due to sickness were significantly more likely not to have had a resection, and non-curative 
disease was associated with substantially higher odds of future needs.  
 
Studies of people with pancreatic cancer are difficult to undertake due to its rarity, severity 
and fast progression. However, the rapid progression and poor survival do mean that the 
effectiveness of interventions may be quickly assessed. Despite some limitations, this study 
makes a valuable contribution to the pancreatic cancer care literature. The longitudinal design 
illuminates a continuing burden of unmet needs over time. Early attention to issues of pain 
and anxiety may reduce current and future unmet supportive care needs in this population. 
Until substantial gains are made in the curative treatment of this disease, optimising 
supportive management is a key priority in maximising patient quality of life.  
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Table 1: Baseline demographic and clinical characteristics of participants and bivariable associations with 
any baseline moderate-to-high unmet needs 
 
Responders 
(n=116) 
Participants with no-to-
low unmet needs (n=35) 
Participants with ≥1 
moderate-to-high 
unmet need (n=81) 
 
  n (%) n (%) n (%) p-valuea 
Age (years)        
Mean (SD) 67.0 (9.5) 68.0 (8.3) 66.6 (10.0) 0.500 
Sex        
Male 70 (60) 22 (31) 48 (69) 0.716 
Female 46 (40) 13 (28) 33 (72)  
Marital Status        
Married/partner 93 (80) 28 (30) 65 (70) 0.976 
Divorce/separated/widowed/never married  23 (20) 7 (30) 16 (70)  
Education        
High school or lower 48   (42) 15 (31) 33 (69) 0.738 
College or higher 67 (58) 19 (28) 48 (72)  
Place of residence        
Major city 54 (47) 15 (28) 39 (72) 0.570 
Inner regional 52 (45) 18 (35) 34 (65)  
Outer regional 10 (9) 2 (20) 8 (80)  
Months post-diagnosis at questionnaire 1        
Mean (SD) 2.9 (1.3) 3.1 (1.5) 2.8 (1.3) 0.344   
Initial place of treatment        
Public hospital  43 (37) 12 (28) 31 (72) 0.728 
Private hospital/specialist rooms 71 (61) 22 (31) 49 (69)  
Disease status         
Resection completed - curative disease  51 (44) 15 (29) 36 (71) 0.991 
Resection failed - locally advanced disease 12 (10) 3 (25) 9 (75)  
Resection failed - metastatic disease 3 (3) 1 (33) 2 (65)  
No resection - locally advanced disease 14 (12) 4 (29) 10 (71)  
No resection - metastatic disease 32 (28) 11 (34) 21 (66)  
No resection - because of age/comorbidities 4 (3) 1 (25) 3 (75)  
Number of comorbidities        
Mean (SD) 2.2 (1.4) 2.5 (1.6) 2.0 (1.4) 0.100 
Had chemotherapy         
No 17 (15) 5 (29) 12 (71) 0.880 
Yes 96 (83) 30 (31) 66 (69)  
     Not stated 3 (3) - - - -  
Anxiety        
Non-case  67 (58) 28 (42) 39 (58) 0.001 
Sub-clinical/clinical case 49 (42) 7 (14) 42 (86)  
Depression        
Non-case  61 (53) 27 (44) 34 (56) 0.001 
Sub-clinical/clinical case 55 (47) 8 (15) 47 (85)  
Social/family wellbeing         
Mean (SD) 23.6 (4.7) 24.0 (5.0) 23.4 (4.5) 0.500 
Pain        
Not at all/a little bit 77 (68) 32 (42) 45 (58) <0.001 
Somewhat/quite a bit/very much 36 (32) 1 (3) 35 (97)  
Had a care coordinator/care plan        
No/not stated 83 (72) 27 (33) 56 (67) 0.430 
Yes 32 (28) 8 (25) 24 (75)  
Accessed palliative care at baseline        
No 65 (56) 19 (29) 46 (71) 0.800 
Yes 51 (44) 16 (31) 35 (69)  
a P-value comparing characteristics for low-to-no needs versus moderate-to-high needs (Chi-squared test for categorical variables, 
t-test for continuous variables).   
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Table 2: Baseline characteristics of participants who did and did not complete the study 
  Reason for cessation of follow-up  
 
Completed 
the study  
n=49 
Too sick or 
died n=27 
>8 months post-
diagnosis n=24 
Other 
n=16  
p-
value1 
  n (%) n (%) n (%) n (%) 
Age (years)      
Mean (SD) 65 (9.5) 70 (8.5) 70 (6.4) 62 (11.7) 0.006 
Marital Status      
Married/partner 40 (82) 20 (74) 19 (79) 14 (88) 0.729 
Divorce/separated/widowed/never married 9 (18) 7 (26) 5 (21) 2 (13)   
Education      
High school or lower 22 (46) 11 (41) 10 (42) 5 (31) 0.738 
College or higher 26 (54) 16 (59) 14 (58) 11 (69)   
Gender      
Male 33 (67) 14 (52) 13 (54) 10 (63) 0.484 
Female 16 (33) 13 (48) 11 (46) 6 (38)   
Disease status      
Curative disease 24 (49) 4 (15) 14 (58) 9 (56) 0.001 
Locally advanced/metastatic disease 25 (51) 23 (85) 10 (42) 7 (44)  
Anxiety           
Non-case 31 (63) 11 (41) 15 (63) 10 (63) 0.220 
Sub-clinical/clinical case 18 (37) 16 (59) 9 (38) 6 (37)  
Depression      
Non-case 27 (55) 10 (37) 14 (58) 10 (63) 0.284 
Sub-clinical/clinical case 22 (45) 17 (63) 10 (42) 6 (38)   
Pain           
Not at all/a little bit 33 (69) 14 (54) 20 (87) 10 (63) 0.165 
Somewhat 6 (13) 6 (23) 3 (13) 4 (25)  
Quite a bit/very much 9 (19) 6 (23) - 2 (13)   
1 Associations with categorical variables were tested using chi-squared analysis and with continuous variables using ANOVA. 
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Table 3. Factors from multivariable analysis associated with current and future reporting of moderate-to-high unmet needs  
 Any needs  Physical needs  Psychological needs 
 Current (n=112)a  Future (n=75)ab  Current (n=112)a  Future (n=75)ab  Current (n=112)a  Future (n=75)ab 
 
Odds ratio  
 
Odds ratio   Odds ratio   Odds ratio   Odds ratio   Odds ratio  
(95% 
confidence 
interval) 
p-
value 
(95% 
confidence 
interval) 
p-
value  
(95% 
confidence 
interval) 
p-
value  
(95% 
confidence 
interval) 
p-
value  
(95% 
confidence 
interval) 
p-
value  
(95% 
confidence 
interval) 
p-
value 
Time                  
Baseline Referent 0.909  N/A 0.725  Referent 0.433  N/A 0.706  Referent 0.501  N/A 0.799 
2 mth follow-up 0.9 (0.5,1.6)   Referent   0.6 (0.3,1.3)   Referent   0.9 (0.5,1.4)   Referent  
4 mth follow-up 0.9 (0.3,2.1)   1.2 (0.5,2.7)   0.7 (0.3,1.7)   1.2 (0.6,2.4)   0.7 (0.3,1.3)   0.9 (0.5,1.7)  
Age (years) 1.0 (0.9,1.0) 0.122  1.0 (0.9,1.0) 0.402  1.0 (0.9,1.0) 0.414  1.0 (0.9,1.0)  0.835  1.0 (0.9,1.0)  0.113  1.0 (0.9,1.0) 0.274 
Disease status                  
Curative Referent 0.506  Referent 0.283  Referent 0.269  Referent 0.089  Referent 0.291  Referent 0.251 
Locally 
advanced 1.7 (0.7,4.1)   1.9 (0.6,6.6)   2.1 (0.8,5.6)   3.6 (1.1,11.4)   0.6 (0.2,1.6)   0.6 (0.2,1.9)  
Metastatic 1.5 (0.5,4.2)   2.7 (0.7,10.0)   1.0 (0.4,2.9)   1.5 (0.5,4.7)   1.5 (0.6,3.8)   2.5 (0.6,10.2)  
Anxiety                  
Non-case Referent 0.003  Referent 0.147  Referent 0.096  Referent 0.523  Referent <0.001  Referent 0.039 
Sub-
clinical/clinical 3.3 (1.5,7.3)   2.5 (0.7,8.6)   2.1 (0.9,5.3)   1.5 (0.5,4.7)   4.2 (2.2,7.9)   2.4 (1.0,5.6)  
Depression:                  
Non-case Referent <0.001  Referent 0.680  Referent <0.001  Referent 0.504  Referent 0.015  Referent 0.043 
Sub-
clinical/clinical 3.2 (1.7,6.0)   1.2 (0.4,3.5)   4.9 (2.2,11.2)   1.4 (0.6,3.3)   2.0 (1.1,3.7)   2.5 (1.0,5.9)  
Pain                  
None - a little bit Referent <0.001  Referent 0.007  Referent <0.001  Referent 0.003  Referent 0.001  Referent 0.065 
Somewhat - 
very much 6.1 (2.4,15.3)   4.9 (1.5,15.4)   10.6 (5.0,22.6)    4.2 (1.6,10.8)   2.8 (1.6,5.0)   2.2 (1.0, 4.9)  
Contextually significant: odds ratio ≥ 2 or ≤ 0.5  
a  4 participants who had no resection because of age/comorbidities were excluded due to model instability with small cell size. 
b 37 participants had only baseline data and were excluded from this analysis. 
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Figure 1. Flow of participant recruitment  
  
Queensland Pancreatic Cancer Study
351 cases enrolled between July 2009 and June 2011  
(i.e. the sub‐study recruitment period) 
Excluded n=97
 Did not give consent to future studies n=29 
 Died before able to approach n=8 
 >8 months post‐diagnosis n=10 
 Considered too sick to approach n=50  
Patient‐Reported Outcome longitudinal sub‐study
254 cases approached 
Not enrolled n=118
 Declined n=57 
 Non‐response =38 
 Died shortly after approached n=23 
Patient‐Reported Outcome longitudinal sub‐study 
136 completed the baseline questionnaire 
Excluded n=20
 >6 months after diagnosis (baseline)  n=14 
 Two data points missing (unusable) n=6 
Analysed at baseline (0‐6 months after diagnosis) n=116
Lost to follow‐up n=37
 Non‐response  n=13 
 Too sick n=6 
 Died n=18 
Analysed at follow‐up 2 months after baseline n=79 
Analysed at follow‐up 4 months after baseline n=49 
Lost to follow‐up/not approached n=30 
 Not approached (>8 months post‐
diagnosis) n=24 
 Non‐response  n=3 
 Died n=3 
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Figure 2. Percent of people experiencing moderate-to-high unmet needs by time of follow-up. 
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Figure 3 Percent of people experiencing moderate-to-high unmet needs by disease status 
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